[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  aponia_analytics [@AponiaAnalytics](/creator/twitter/AponiaAnalytics) on x 4949 followers Created: 2025-07-14 18:57:45 UTC 🦉 Low doses and early discontinuation drive weaker outcomes. Only patients who stayed on full doses (2.4 mg semaglutide, XX mg tirzepatide) matched trial-level weight loss. #obesity #GLP1 $NVO $LLY XXX engagements  **Related Topics** [$lly](/topic/$lly) [weight loss](/topic/weight-loss) [$mngl](/topic/$mngl) [$nvo](/topic/$nvo) [stocks healthcare](/topic/stocks-healthcare) [eli lilly](/topic/eli-lilly) [Post Link](https://x.com/AponiaAnalytics/status/1944833716280238440)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
aponia_analytics @AponiaAnalytics on x 4949 followers
Created: 2025-07-14 18:57:45 UTC
🦉 Low doses and early discontinuation drive weaker outcomes. Only patients who stayed on full doses (2.4 mg semaglutide, XX mg tirzepatide) matched trial-level weight loss. #obesity #GLP1 $NVO $LLY
XXX engagements
Related Topics $lly weight loss $mngl $nvo stocks healthcare eli lilly
/post/tweet::1944833716280238440